|
Aurobindo Pharma Limited
(www.aurobindo.com), headquartered at Hyderabad,
India, manufactures generic pharmaceuticals and
active pharmaceutical ingredients. The company
has received approvals for most of the targeted
API and formulation facilities from leading
regulatory agencies such as US FDA, UK MHRA,
WHO, Health Canada, MCC South Africa.
The company’s robust product
portfolio is spread over 6 major
therapeutic/product areas encompassing
Antibiotics, Anti-Retrovirals, CVS, CNS,
Gastroenterologicals, and Anti-Allergics.
The formulation portfolio is built on six
technology platforms such as immediate release
generics, SR/CR generics, orally
disintegrating/mouth dissolving generics,
combination products, sterile/lyophilized
generics and liquids/dry syrups.
Aurobindo has filed over 100 DMFs
and 75 ANDAs for the USA market in addition to
filings in other countries. The pace of filings
is matched by rapid product approvals from
various markets. Till date Aurobindo received 37
ANDA approvals (both final and tentative) from
US FDA.
Aurobindo operates in over 100
countries and markets over 180 APIs and 250
formulations |
PRESS
ROOM
